Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivosidenib - Agios Pharmaceuticals

Drug Profile

Ivosidenib - Agios Pharmaceuticals

Alternative Names: AG-120; CS 3010; TIBSOVO

Latest Information Update: 24 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agios Pharmaceuticals
  • Developer AbbVie; Agios Pharmaceuticals; CStone Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cyclobutanes; Nitriles; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Cholangiocarcinoma; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase III Cholangiocarcinoma
  • Phase I Glioma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 18 Dec 2019 Ivosidenib - Agios Pharmaceuticals receives Breakthrough Therapy status for Myelodysplastic syndromes in USA
  • 07 Dec 2019 Efficacy data from a phase I/II trial in Acute myeloid leukaemia presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
  • 22 Nov 2019 Adverse events, pharmacokinetic, phamacodynamics and efficacy data from a phase I trial in Glioma released by Agios Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top